期刊
EUROPEAN UROLOGY ONCOLOGY
卷 3, 期 4, 页码 433-452出版社
ELSEVIER
DOI: 10.1016/j.euo.2020.02.001
关键词
Renal cell cancer; Ablative therapy; Partial nephrectomy; Prognosis; European Association of Urology guidelines
资金
- Pfizer
- Ipsen
- Novartis
- Roce
- AstraZeneca
- Eisai
- Merck MSD
- Exelixis/Ipsen
- BMS
- Astellas
- Janssen-Cilag
- Ferring
- Wyeth
- Merck
- Takeda
- GlaxoSmithKline
- Roche
- Bayer
- Aveo
The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel performed a protocol-driven systematic review (SR) on thermal ablation (TA) compared with partial nephrectomy (PN) for T1N0M0 renal masses, in order to provide evidence to support its recommendations. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed, and only comparative studies published between 2000 and 2019 were included. Twenty-six nonrandomised comparative studies were included, recruiting a total of 167 80 patients. Risk of bias (RoB) assessment revealed high or uncertain RoB across all studies, with the vast majority being retrospective, observational studies with poorly matched controls and short follow-up. Limited data showed TA to be safe, but its long-term oncological effectiveness compared with PN remains uncertain. A quality assessment of pre-existing SRs (n = 11) on the topic, using AMSTAR, revealed that all SRs had low confidence rating, with all but two SRs being rated critically low. In conclusion, the current data are inadequate to make any strong and clear conclusions regarding the clinical effectiveness of TA for treating T1N0M0 renal masses compared with PN. Therefore, TA may be cautiously considered an alternative to PN for T1N0M0 renal masses, but patients must be counselled carefully regarding the prevailing uncertainties. We recommend specific steps to improve the evidence base based on robust primary and secondary studies. Patient summary: In this report, we looked at the literature to determine the effectiveness of thermoablation (TA) in the treatment of small kidney tumours compared with surgical removal. We found that TA could cautiously be offered as an option due to many remaining uncertainties regarding its effectiveness. (c) 2020 Published by Elsevier B.V. on behalf of European Association of Urology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据